文献速递精神分裂症与精神病性障碍

神经代谢物与精神病抗精神病药反应:一项大样本汇总分析

Neurometabolites and Antipsychotic Response in Psychosis: A Mega-Analysis.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

该研究基于18项研究的1189例个体数据及23项研究的荟萃分析,比较抗精神病药无反应与有反应精神病患者的内侧额叶神经代谢物。无反应者内侧额叶谷氨酸、谷氨酸+谷氨酰胺、胆碱和肌醇升高,提示这些标志物与治疗无反应相关。

要点

  • 抗精神病药无反应者内侧额叶谷氨酸、谷氨酸+谷氨酰胺、胆碱和肌醇较有反应者升高。
  • 首发性精神病前瞻性设计中,无反应者内侧额叶谷氨酸+谷氨酰胺升高。
  • 符合治疗抵抗标准者肌醇升高最明显。

核心结论

  • 精神病抗精神病药无反应与内侧额叶谷氨酸、胆碱和肌醇升高相关。
  • 这些标志物的升高支持继续研究作用于谷氨酸和炎症通路的干预措施。

研究设计与样本

  • 汇总分析纳入18项研究的1189例参与者,其中无反应者476例、有反应者427例、健康对照286例。
  • 荟萃分析纳入23项研究共1844例参与者,分析标准化均数差和变异性。
  • 个体参与者数据采用以研究为随机效应的线性混合模型分析,并提取已发表的组均数和标准差进行荟萃分析。

主要发现

  • 与有反应组相比,无反应者内侧额叶谷氨酸升高(Glass Δ = 0.21;P = .02)。
  • 与有反应组相比,无反应者内侧额叶谷氨酸+谷氨酰胺升高(Glass Δ = 0.29;P = .002)。
  • 与有反应组相比,无反应者内侧额叶胆碱升高(Glass Δ = 0.22;P = .03)。
  • 与有反应组相比,无反应者内侧额叶肌醇升高(Glass Δ = 0.35;P = .001)。
  • 首发性精神病前瞻性设计中,无反应者较有反应者内侧额叶谷氨酸+谷氨酰胺升高(Glass Δ = 0.41;P = .002);符合治疗抵抗标准者肌醇升高最明显(Glass Δ = 0.64;P = .001)。

关键数值与推荐

  • 荟萃分析显示无反应者较有反应者内侧额叶胆碱和肌醇升高。

临床怎么用

  • 内侧额叶谷氨酸、胆碱和肌醇升高或有助于识别抗精神病药无反应风险。
  • 针对谷氨酸通路和炎症通路的干预值得在精神病和 schizophrenia 中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Revealing neurobiological markers of antipsychotic nonresponse in psychosis may aid outcome prediction and inform novel treatment targets. OBJECTIVE: To examine differences in neurometabolites in antipsychotic nonresponsive compared to antipsychotic-responsive psychosis using individual participant data and meta-analysis. DATA SOURCES: Web of Science was searched for studies published between January 1, 1980, and November 1, 2025. Authors of 21 eligible studies identified before August 2024 were invited to contribute individual participant data. STUDY SELECTION: Eighteen studies examining neurometabolites by treatment response in psychosis contributed individual participant data for the mega-analysis. These studies plus a further 5 studies were included in the meta-analyses of standardized mean differences and variability. DATA EXTRACTION AND SYNTHESIS: Individual participant data were analyzed using linear mixed models with study as a random effect. Subgroup analyses examined prospective designs and treatment-resistant samples. Published group means and standard deviations were extracted for meta-analyses. MAIN OUTCOMES AND MEASURES: Group differences in glutamate, glutamate plus glutamine, choline, myo-inositol, N-acetylaspartate, γ-aminobutyric acid, and glutathione in the medial frontal cortex, dorsolateral prefrontal cortex, thalamus, and basal ganglia. RESULTS: The mega-analysis included 1189 participants from 18 studies; of these, 476 were treatment nonresponders (mean [SD] age, 33.0 [12.5] years; 340 male), 427 were treatment responders (mean [SD] age, 30.3 [11.5] years; 299 male), and 286 were healthy control individuals (mean [SD] age, 31.0 [12.5] years; 170 male). Compared with the antipsychotic response group, nonresponders showed elevations in medial frontal glutamate (Glass Δ = 0.21; P = .02), glutamate plus glutamine (Glass Δ = 0.29; P = .002), choline (Glass Δ = 0.22; P = .03), and myo-inositol (Glass Δ = 0.35; P = .001); similar elevations were observed relative to control individuals. Elevated medial frontal glutamate plus glutamine in antipsychotic nonresponders compared with responders was also observed prospectively in first-episode psychosis (Glass Δ = 0.41; P = .002), whereas myo-inositol elevations were greatest in individuals meeting criteria for treatment-resistance (Glass Δ = 0.64; P = .001). The meta-analysis of 23 studies (1844 participants) also showed elevated medial frontal choline and myo-inositol in antipsychotic nonresponse compared with response. CONCLUSIONS AND RELEVANCE: These findings provide evidence of an association between antipsychotic nonresponse in psychosis with elevations in medial frontal glutamate, choline, and myo-inositol. The presence of elevations in these markers supports the continued investigation of glutamate-acting and inflammatory pathway-associated interventions for psychosis and schizophrenia.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. King B, Bojesen KB, Crisp C, et al. Neurometabolites and Antipsychotic Response in Psychosis: A Mega-Analysis. JAMA Psychiatry. 2026. PMID: 42340705. doi:10.1001/jamapsychiatry.2026.1674

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。